Laurion Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Laurion Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,810	Closed	-$102K	–	580
2023 Q2	$102K	Buy	+3,810	New	+$164K	﹤0.01%	520
2021 Q3	–	Sell	-4,052	Closed	-$627K	–	775
2021 Q2	$627K	Sell	4,052 -61,312	-94%	-$8.9M	﹤0.01%	489
2021 Q1	$10.3M	Hold	65,364	–	–	0.06%	250
2020 Q4	$15.2M	Buy	65,364 +55,381	+555%	+$12.8M	0.12%	150
2020 Q3	$2.19M	Buy	+9,983	New	+$2.44M	0.03%	301
2020 Q2	–	Sell	-667	Closed	-$192K	–	1041
2020 Q1	$192K	Buy	+667	New	+$184K	﹤0.01%	675
2014 Q3	–	Sell	-1,213	Closed	-$847K	–	349
2014 Q2	$847K	Buy	+1,213	New	+$565K	0.02%	213

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Laurion Capital Management's KPTI Position: Q3 2023 in Review

Laurion Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 3,810 shares — an estimated $102K sold.

Laurion Capital Management first reported a position in KPTI in Q2 2014 and held it in 7 quarters. The position peaked at $15.2M in Q4 2020. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

Laurion Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
Laurion Capital Management sold 3,810 Karyopharm Therapeutics shares in Q3 2023, an estimated $102K.
Laurion Capital Management first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 7 quarters.
Laurion Capital Management's Karyopharm Therapeutics position peaked at $15.2M in Q4 2020.
118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.